Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanisms

1 Jun 2021

Abstract excerpt

BACKGROUND: Pharmacological autophagy enhancement constitutes a preclinically validated strategy for preventing or treating most major age-associated diseases. Driven by this consideration, we performed a high-content/high-throughput screen on 65 000 distinct compounds on a robotized fluorescence microscopy platform to identify novel autophagy inducers. RESULTS: Here, we report the discovery of picropodophyllin...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Autophagy in Disease and Therapy
Share to Cancer, Hypoxia, and Metabolism
Share to Ginseng Biological Effects and Applications

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 34127545
DOI: 10.1136/jitc-2021-002722

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

IGF1 receptor inhibition amplifies the effects of cancer drugs by autophagy and immune-dependent mechanismsPMID 34127545Read ↗

GLP-1 Targeting Agents Impair Chemoimmunotherapy Effectiveness in Triple-Negative Breast CancerSemantic proximity Read ↗

Activated kinase screening identifies the IKBKE oncogene as a positive regulator of autophagySemantic proximity Read ↗

Targeting the insulin-like growth factor-1 receptor by picropodophyllin as a treatment option for glioblastomaSemantic proximity Read ↗

Bi-steric mTORC1-selective Inhibitors activate 4EBP1 reversing MYC-induced tumorigenesis and synergize with immunotherapySemantic proximity Read ↗

Screening of Stereochemically Defined 2,5-Diketopiperazines Identifies Autophagy Inducers without mTORC1 SuppressionSemantic proximity Read ↗

Rapalogs downmodulate intrinsic immunity and promote cell entry of SARS-CoV-2Semantic proximity Read ↗

Bi-steric mTORC1 inhibitors induce apoptotic cell death in tumor models with hyperactivated mTORC1Semantic proximity Read ↗

A putative biomarker signature for clinically effective AKT inhibition: correlation of in vitro, in vivo and clinical data identifies the importance of modulation of the mTORC1 pathway.Semantic proximity Read ↗

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumoursSemantic proximity Read ↗

The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signalingSemantic proximity Read ↗

A novel phosphatidylinositol 3-kinase (PI3K) inhibitor directs a potent FOXO-dependent, p53-independent cell cycle arrest phenotype characterized by the differential induction of a subset of FOXO-regulated genesSemantic proximity Read ↗

Phenotypic screening platform identifies statins as enhancers of immune cell-induced cancer cell deathSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.